Skip to main content
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. — Investor Relations & Filings

Ticker · OTLK ISIN · US69012T3059 LEI · 5493007AWUJ6HPMCBH11 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2024-04-17 Director's Dealing
Country US United States of America
Listing US OTLK

About Outlook Therapeutics, Inc.

https://outlooktherapeutics.com/

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for ophthalmic indications. The company's lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). If approved in the United States, it would be the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. The therapy, under the brand name LYTENAVA™ (bevacizumab gamma), has received Marketing Authorization from the European Commission and the UK's MHRA for the treatment of wet AMD. The monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF).

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-04-17 English
Regulatory Filings 2024
Regulatory Filings
2024-04-16 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 15, 2024, by Outlook Therapeutics, Inc. The content describes the closing of a private placement of common stock and warrants, including details about the securities issued, purchase price, and exemptions relied upon. This is a disclosure of a financing event, specifically a private placement of equity securities. The document is not a full financial report, earnings release, or management discussion, but rather an update on capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4589 characters, which is consistent with a typical 8-K filing for such an event, and it contains substantive details about the financing transaction.
2024-04-15 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an at-the-market sales agreement for common stock. It details the terms of a stock offering, including the amount of stock to be sold, the sales agent, commissions, and risk factors. The document is a detailed offering document used to raise capital through the sale of common stock. This type of document is a capital markets financing update rather than a financial report, management discussion, or regulatory filing unrelated to financing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief summary, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2024-04-12 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes an amendment to an existing at-the-market sales agreement related to the issuance and sale of common stock, including references to registration statements and prospectus supplements. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is not a proxy, earnings release, or management discussion. It is a regulatory announcement about a financing agreement amendment. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 5870 characters, sufficient to contain substantive information about the financing update rather than a brief announcement. Confidence is high due to the clear nature of the filing and its content.
2024-04-12 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-04-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.